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ABSTRACT
Background: Thyroid cancer is the most common endocrine malignancy. Studies have observed an anti-
cancer effect for vitamin D and found that polymorphisms of vitamin D receptors can influence the
prevalence of various cancers. The present study investigated the serum level of vitamin D and FokI,
BsmI and Tru9I polymorphisms of vitamin D receptors. Methods: Forty patients with medullary thyroid
cancer and 40 healthy controls were investigated. The genomic DNA of the subjects was extracted using
saturated salt/proteinase K and investigated by PCR sequencing. Serum levels of vitamin D were eval-
uated by ELISA. The results were analyzed in SPSS and GraphPad Prism 5 software. Results: The
genotypic and allelic frequencies of FokI and BsmI polymorphisms showed no significant differences
between test and control groups. For Tru9I polymorphism, Tt genotype and t allelic frequency in the test
group were significantly different from those of the control group. Also, we found Tt genotype and
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t allelic frequency to be significantly associated with medullary thyroid cancer (MTC) type and the
agressiveness of the disease. The average serum vitamin D level was 23.32 ng/mL and 18.95 ng/mL for
patients and controls, respectively, and the difference between the two groups was statistically significant.
Moreover, we found high serum vitamin D level to be associated with t allelic frequency. Conclusions:
Unexpectedly, the mean serum vitamin D level of the test group was significantly higher than that of the
control group. Tru9I polymorphism was found to be significantly correlated with the prevalence of
medullary thyroid carcinoma.
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INTRODUCTION
Thyroid cancer is the most common endocrine malignancy and accounts for 1–2% of all
cancers. Epidemiological studies have reported a gradual increase in its overall incidence [7, 38].
Thyroid cancers can be divided into four main subtypes including papillary, follicular, medullary
and anaplastic [8, 11]. Medullary thyroid cancer (MTC) is a rare form of thyroid cancer that
accounts for 5–8% of all thyroid cancers. MTC originates from the parafollicular cells (C cells),
whereas the other three types originate from follicular cells.
Several factors are involved in the growth of the thyroid gland. Thyroid-stimulating
hormone (TSH) plays a major role in regulating growth and differentiation of thyroid cells.
TSH stimulates the production of molecules involved in intracellular signal transduction,
including cAMP [44], iodine uptake and cell growth [29]. The active form of vitamin D (1,25-
(OH)2 D3) binds to its receptor (VDR) using genomic and non-genomic mechanisms that
inhibit the proliferative effect of TSH on thyroid cells. It is logical to propose that vitamin D
plays a role in regulating thyroid gland cell proliferation. Binding of 1,25-(OH)2 D3 to its
receptor results in pleiotropic effects regulating calcium-phosphate metabolism, cell prolif-
eration, differentiation, apoptosis, angiogenesis and metastasis. Vitamin D can thus be
described as a very important agent in the anti-cancer response [3]. Accordingly, many
studies have shown the anticancer effects of vitamin D on breast, prostate, colon and endo-
crine cancers [20].
In mammals, the expression of VDR is high in metabolic tissue, including the intestine,
kidney, skin and thyroid gland. VDR is also expressed in high levels in tumor tissue [16]. This
nuclear receptor function is affected by the presence of various genetic polymorphisms [26].
Several polymorphisms have been identified in the introns and exons of the VDR gene. These
include Tru9I and BsmI on intron 8, FokI on exon 2 and TaqI on exon 9 [33]. FokI is located on
the 50 end and the other three polymorphisms are located on the 30 end of the VDR gene [21].
Several studies have found a relationship between VDR gene polymorphisms and the risk of
various cancers [30, 35, 46]. Also, we have previously demonstrated an association between RET
gene polymorphisms and the risk of medullary thyroid cancer [18]. It could be concluded that
changes in the vitamin D system can affect cancer progression. The current study evaluated
serum levels of vitamin D and polymorphisms of the VDR gene in patients with MTC and
compared the results with those of a healthy control group.
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MATERIALS AND METHODS
Sample preparation
The current study was carried out after obtaining prior permission from the Institutional Ethical
Committee of the Cellular and Molecular Endocrinology Research Center at Shahid Beheshti
University of Medical Sciences (No: IR.ARUMS.REC.93.66; dated: 28/2/2015). Written informed
consent was received from all participants.
Forty patients with MTC including, 30 hereditary (29 FMTC and 1 MEN2B) and 10 sporadic
cases were enrolled in the present study. The diagnoses were confirmed by pathological ex-
amination of thyroid tissue samples. Study controls were 40 age- and gender-matched normal
healthy persons without a family history of thyroid carcinoma and with no autoimmune dis-
eases, selected from the healthy staff members of Cellular and Molecular Endocrinology
Research Center at Shahid Beheshti University of Medical Sciences.
About 10 mL of peripheral blood was obtained from each participant. Genomic DNA was
extracted from nuclear cells of the peripheral blood using a standard salting-out procedure [31].
The concentration of the DNA sample was evaluated by UV spectrophotometry.
Polymerase chain reaction and genotyping
The polymerase chain reaction (PCR) assay was performed in a final volume of 35 mL in pre-
mixed microtubes (Bioneer; South Korea) containing 1 U Taq polymerase, dNTP (250 mM),
Tris-HCl (10 mM), KCl (30 mM) and MgCl2 (1.5 mM). The following were added to each
microtube: 1 mL (5–10 pmol) of each amplification primer, 1 mL (5–50 ng) of DNA and 32 mL of
sterile distilled water. PCR was carried out for 30 cycles (each cycle consisted of 35 s at 94 8C for
denaturation, 1 min at 60.5 8C for annealing and 45 s at 72 8C for extension) with an initial
denaturation at 95 8C and final extension at 72 8C for 10 min. The 237 bp fragment encompassing
the FokI-rs2228570 polymorphic site and the 339 bp fragment encompassing the BsmI-rs1544410
and Tru9I-rs757343 polymorphic sites were amplified using the specific primers (Table 1).
The purified PCR products were sequenced using forward primers by Bioneer (South Korea).
Sequences were analyzed using Chromas Lite software (Technelysium) and verified against the
sequence at the NCBI GenBank (National Center for Biotechnology Information) (Fig. 1).
Measurement of 25-(OH) D3
The concentration of 25-(OH) D3 was measured in the plasma of patients with MTC (n 5 40)
and those in the control group (n 5 40) using an Elisa kit according to instructions by the
manufacturer (Calbiotec; USA).




BsmI & Tru9Ia F:5-CAGAGTGTGCAGGCG-3
R:5-CCCTCTTTGGACCTCATCAC-3
aBsmI and Tru9I are located on intron 8, therefore both could be amplified using a single pair of primers.
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Statistical analysis
The association between MTC and genotypes was evaluated by the Chi-square test using SPSS
(version 25). Fisher's Exact probability test was applied for analyzing the Tru9I polymorphism since
the tt allelic frequency for control groupwas zero. The odds ratios and their 95% confidence intervals
were estimated. The frequency distributions of the VDR polymorphisms were tested for Hardy–
Weinberg equilibrium using the Chi-square test (df 5 1). A subgroup analysis was performed to
evaluate the association between VDR polymorphism (Tru9I) and MTC type, pathological findings
and gender of patients using Chi-square test. Also, Chi-square test was used to investigate the
association between vitamin D level and gender of study subjects, VDR polymorphism (Tru9I),
MTC type and pathological findings. Since the vitamin D levels were not normally distributed, the
comparison of vitamin D between the test and control groups was estimated by the Mann–Whitney
test using GraphPad Prism 5. A P-value of < 0.05 was considered significant.
RESULTS
A total of 40 patients with MTC (mean age 36 ± 7.57) and 40 healthy controls (mean age 33 ±
6.02) were included in this study. Analysis showed no statistically significant difference in mean
age between the test and control groups. Distribution of patients by gender, age of disease onset
and MTC type are shown in Table 2.
Fig. 1. VDR DNA sequencing results: (A) and (B) show results in exon 2. Peaks in (A) show the natural
sequence of DNA and peaks in (B) show the expected heterozygous mutation (Fok-rs2228570 T > C). (C),
(D), (E) and (F) show results in intron 8. (C) and (E) show natural sequence of DNA, respectively. (D) and
(F) show expected heterozygous mutations (BsmI-rs1544410 A > G) and (Tru9I-rs757343 A > G),
respectively
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Genotypes
All genotypes in the FokI and BsmI polymorphisms displayed similar frequencies in the test and
control groups and no association between these polymorphisms and the risk of MTC was
observed (P > 0.05). For the Tru9I polymorphism, the Tt genotype frequency in the test group
Table 2. Baseline characteristics of patients/kindreds with medullary thyroid carcinoma indexed by age of













1 M FMTC 17 21 M FMTC 32
2 M FMTC 33 22 F FMTC 26
3 M Sporadic 54 23 F FMTC 28
4 M Sporadic 61 24 F FMTC 43
5 M Sporadic 48 25 F MEN2B 11
6 F FMTC 25 26 F FMTC 32
7 F FMTC 46 27 M FMTC 13
8 M Sporadic 57 28 M Sporadic 47
9 F FMTC 35 29 F Sporadic 50
10 M FMTC 48 30 F FMTC 48
11 M FMTC 24 31/1 F FMTC 25
12 F FMTC 21 31/2 F FMTC 25
13 F FMTC 22 31/3 F FMTC 27
14 F FMTC 29 32 F FMTC 37
15 F FMTC 37 33 M FMTC 28
16 F FMTC 20 34 F FMTC 38
17 M FMTC 37 35 F Sporadic 61
18 F FMTC 36 36 M Sporadic 32
19 F Sporadic 44 37 F Sporadic 49
20 F FMTC 40 38 F FMTC 34
M: Male, F: Female, MTC: Medullary Thyroid Cancer, FMTC: Familial Medullary Thyroid Cancer,
MEN2B: Multiple Endocrine Neoplasia 2B.
Table 3. Frequencies, P-values and Odds ratios of VDR polymorphisms in patients with medullary thyroid
cancer and controls
Polymorphism Genotype Carcinoma Control P-value OR (95% CI)
FokI FF 1 (2.5%) 3 (7.5%) Reference Genotype
Ff 12 (30.0%) 12 (30.0%) 0.876 1.08 (0.41–2.84)
Ff 27 (67.5%) 25 (62.5%) 0.611 3.24 (0.32–33.22)
BsmI BB 23 (57.5%) 16 (40.0%) Reference Genotype
Bb 11 (27.5%) 20 (50.0%) 0.502 2.61 (0.98–6.92)
bb 6 (15.0%) 4 (10.0%) 0.953 0.96 (0.23–3.95)
Tru9I TT 21 (52. 5%) 33 (82. 5%) Reference Genotype
Tt 18 (45.0%) 7 (17. 5%) 0.006 0.24 (0.09–0.69)
tt 1 (2. 5%) 0 (0%) 1.00 (1.62–2.53)
OR: Odds Ratio; CI: Confidence Interval
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Table 4. Allele frequencies, P-values and Odds ratios of VDR polymorphisms in patients with medullary
thyroid cancer and controls
Polymorphism Allele Carcinoma Control P-value OR (95% CI)
FokI F 14 (17.5%) 18 (22.5%) Reference Allele
F 66 (82.5%) 62 (77.5%) 0.429 1.37 (0.63–2.98)
BsmI B 57 (71.25%) 52 (65.0%) Reference Allele
b 23 (28.75%) 28 (35.0%) 0.396 1.33 (0.68–2.60)
Tru9I T 60 (75.0%) 73 (91.25%) Reference Genotype
T 20 (25.0%) 7 (8.75%) 0.006 0.29 (0.11–0.73)
OR: Odds Ratio; CI: Confidence Interval.















TT 8 57.1 13 50.0 0.242 0.556
(0.20–
1.49)
Ttþtta 6 42.9 13 50.0





TT 13 43.3 8 80.0 0.044 5.23
(0.947–
28.90)










TT 3 21.4 18 69.2 0.004 0.121
(0.026–
0.557)
Ttþtt 11 78.6 8 30.8
aThere was only one patient with “tt” genotype in our population (a female with non-aggressive FMTC).
None of the controls showed “tt” genotype. bCriteria for aggressive disease include: patients with stage III
and IV (A, B or C) MTC or those patients who developed metastasis during the study period.
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20 60.6 3 42.9 14 66.7 5 26.3
aSampling was performed in winter and the cutoff point was determined based on the median vitamin D level of control samples.
bThere was only one patient with “tt” genotype in our population (a female with non-aggressive FMTC and a vitamin D level of more than 18.2 ng/







was significantly different from control group (P 5 0.006). The frequencies of FokI, BsmI and
Tru9 genotypes, P-values and odds ratio (OR) for the test and control groups are shown in
Table 3.
The allelic frequencies in the polymorphisms in the test group were also determined. Except
for Tru9I, there were no notable differences in allelic prevalence between groups (Table 4). For
the Tru9I polymorphism, the frequency of the t allele was significantly different between groups
(P 5 0.006). Statistical analysis showed that the frequency distribution of VDR polymorphisms
in the study population attained Hardy-Weinberg equilibrium (P > 0.05).
Subgroup analysis of Tru9I genotype
The associations between the Tru9I polymorphism and gender, MTC type and disease aggres-
siveness were analyzed within the MTC patient group. According to the cross-table (Table 5), no
significant association is observable between Tru9I genotype and the gender of patients. However,
there is a strong association between disease aggressiveness and Tru9I genotype. According to our
results the frequency of Tt and tt genotypes is significantly higher in patients with aggressive
disease compared to patients with non-aggressive tumors (P 5 0.004). It should be noted that the










































6 42.9 13 50.0
aSampling was performed in winter and the cutoff point was determined based on the median vitamin D
level of control samples. bThere was only one patient with MEN2B disease in our population who was
excluded from this analysis. cCriteria for aggressive disease include: patients with stage III and IV (A, B or
C) MTC or those patients who developed metastasis during the study period.
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majority of t alleles were present in Tt genotype, and there was only one patient with tt genotype
who was a female with non-aggressive FMTC. Also, the Tt and tt genotypes were more frequent in
patients with FMTC compared to those with sporadic tumors (P 5 0.044).
25-(OH) D3 plasma level
Plasma levels of 25-(OH) D were measured for the participants of both groups. A cutoff point
was established to be used for categorizing study subjects into groups with high and low serum
vitamin D levels. The cutoff point was determined based on the median of vitamin D levels
obtained from control samples (18.2 ng/mL). Low vitamin D level (≤18.2 ng/mL) was more
frequent in female controls (P 5 0.031). Presumably, this is the result of clothing habits in the
Iranian population. However, no significant difference in the distribution of high and low
vitamin D levels was observable between male and female patients (Table 6). Our results show
no significant association between serum vitamin D level and Tru9I polymorphism within the
control group, whereas high vitamin D level (≥18.2 ng/mL) is more frequent in patients with Tt
Fig. 2. Mean serum vitamin D level in test and control group (P 5 0.02)
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and tt genotypes (P 5 0.011) (Table 6). We also performed a subgroup analysis to evaluate the
association of serum vitamin D level with MTC type and pathological findings (Table 7). Ac-
cording to our results there is no significant association between serum vitamin D level and
disease aggressiveness, whereas the frequency of high vitamin D level in patients with FMTC is
significantly higher than patients with sporadic MTC (P 5 0.017). The average serum level of
vitamin D was 23.32 ng/mL for the test group and 18.95 ng/mL for the control group, and this
difference was statistically significant (P 5 0.02) (Fig. 2).
DISCUSSION
Previous studies have shown an association between the serum levels of leptin, vaspin and
medullary thyroid cancer [17, 19]. To our knowledge, the present work is the first study eval-
uating the serum level of vitamin D and FokI, BsmI and Tru9I polymorphisms in patients with
MTC compared to a healthy control group. Vitamin D has a role in different pathways,
including those involved in anticancer activity, inhibition of cell proliferation and invasion,
angiogenesis and metastasis of cancer cells [20, 26]. Previous findings indicate that dysfunction
of VDR or vitamin D deficiency can increase the risk of chronic diseases including cancer [47].
The antitumoral effect of vitamin D through its nuclear receptor (VDR) is well-documented.
Previous findings indicate that increased local action of vitamin D is associated with differen-
tiation, reduced proliferation and favorable prognosis in papillary thyroid carcinoma (PTC)
[25]. Moreover, the antiproliferative effect of vitamin D on different thyroid cell lines – espe-
cially on papillary, follicular and anaplastic cells – has been investigated, mostly attributing an
anti-proliferative activity to vitamin D analogs, which is most likely mediated through over-
expression of the tumor suppressor p27 [5, 32]. However, the results by the studies concerning
the antitumoral effect of vitamin D on C cells are controversial. There is almost consensus upon
a decreasing effect of 1,25-(OH)2 D3 (calcitriol) on calcitonin secretion [36, 48]. However, the
data about proliferative effect of vitamin D on C cells are very inconsistent. In contrast to
antitumorigenic activity of vitamin D on most cancer cells, some findings indicate that vitamin
D treatment results in enhanced cell proliferation in C cells (TT cell line) through increased gene
expression of the c-myc oncogene [2, 6, 48, 49, 50]. These findings may partly explain the
inconsistency of our results on vitamin D level with other studies. Based on the literature, the
association between low vitamin D level and increased risk of most cancers is evident. However,
for thyroid cancers, there are few studies evaluating the mentioned relationship. The data from
clinical studies provide inconsistent information regarding the relationship between vitamin D
status and risk of thyroid cancers [23, 27, 28, 41, 42, 45]. To our knowledge, there is only one
isolated study reporting results consistent with our data on on vitamin status and MTC. This study
introduces vitamin D supplementation as a risk factor for medullary thyroid cancer (OR: 1.8) [40].
Referring to our results, it is clear that although MTC patients exhibit higher vitamin D levels in
comparison to control subjects, the mean vitamin D level is lower than the normal range for both
MTC patients and the control group. It is very important to note that the vitamin D level in the
Iranian population is significantly lower than what is established as the normal range by the world
health authorities, and this is possibly due to the clothing, cultural and social norms.
VDR genes are located on the long arm of chromosome 12 and comprise 8 protein coding
exons (exons 2–9) and 6 non-translated exons (exons a1-f1). Studies have shown that single
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nucleotide polymorphisms on exon 2 (FokI), intron 8 (BsmI and Tru9I) and exon 9 are asso-
ciated with increased risk of ovarian [14], breast [43], colon [35], prostate [22], skin [9],
follicular and papillary thyroid [37] cancers. The FokI polymorphism, located on the 50 end, is a
T to C substitution in the initial codon and increases the transcriptional activity of the VDR. The
resulting difference of three amino acids in VDR length may affect the function of the protein.
The polymorphisms located on the 30 end of the VDR gene do not alter the amino acid
sequence; however, it has been reported that the BsmI and Tru9I polymorphisms on the 30 end
may alter transcriptional activity and mRNA degradation [1].
In the present study, the genotypes and alleles of the FokI and BsmI polymorphisms showed
no significant association with the risk of MTC. For the Tru9I polymorphism, the Tt genotype
and t allele frequencies in the test group were significantly different from the control group,
indicating a considerable increased risk for MTC.
A similar study that evaluated vitamin D receptor polymorphism in patients with
follicular and papillary thyroid cancer showed a significant association between FokI poly-
morphism and follicular cancer, but not papillary thyroid cancer. TaqI and BsmI poly-
morphisms showed no significant relationship [37]. Another similar study found no
significant association between TaqI, Tru9I and BsmI polymorphisms with follicular and
papillary thyroid cancers in the Iranian population; however, there was a significant
difference in allele frequencies of the Tru9I polymorphisms between the test and control
groups [15].
Significant associations between TaqI, Tru9I and BsmI polymorphisms and increased risk of
melanoma, prostate, breast and ovarian cancers have been documented in previous studies [10,
24, 46]. Controversially, other studies have observed no significant association between these
polymorphisms and prostate and ovarian cancer [4, 34].
Unexpectedly, in our study population, the plasma level of 25–(OH) D3 in the MTC group
was significantly higher than in control subjects, whereas many studies reported an inverse
relationship between sera levels of vitamin D and colon [13], breast [39], prostate [12] and
follicular thyroid (37) cancer. Overall, the epidemiological evidence suggests limited and
controversial results about this relationship [12, 39].
The results of the present study demonstrated that the Tru9I polymorphism of the VDR
gene may commonly contribute to the risk of medullary thyroid cancer. Since, the present study
is the first one focusing on patients diagnosed with MTC, and the sample size was relatively
small due to the low rate of prevalence of this cancer, more studies with larger sample sizes are
needed to confirm the results.
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